Optimus Outcome has acquired Autism Acumen, the company said.
“The acquisition of Acumen will accelerate our developments to optimize therapy outcomes for children with autism while improving care management for families,” said Jonathan Wright, CEO of Optimus Outcome. “The Acumen technology fits perfectly into our development strategy and accelerates our own technology development plans. I am very excited to work with Jessica and Fred as advisors in this early growth phase of Optimus Outcome.”
In connection with the acquisition, Jessica Owens and Fred Cohen, M.D., D.Phil., Partner and Managing Director of TPG Biotech and a board member of Acumen, will join Optimus Outcome as advisors.
Optimus Outcome, is offering and developing lifecycle tools to help make autism more manageable.